CClinicalTrials.gg
RecruitingNCT07604220EXODACSUpdated Aug 17, 2026

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

An observational study in Cardiac Sarcoidosis, Sarcoidosis of the Heart and Sarcoidosis With Myocarditis, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Mayo Clinic · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
115
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.

02

Conditions studied

  • Cardiac Sarcoidosis
  • Sarcoidosis of the Heart
  • Sarcoidosis With Myocarditis
  • Sarcoidosis, Cardiac

Browse trials for

Keywords

  • cardiac sarcoidosis
  • FDG-PET
  • disease activity
  • proteomics
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.

Inclusion criteria

  • Adults ≥18 years.
  • Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.
  • Undergoing FDG-PET as part of standard care.
  • Ability to provide informed consent.

Exclusion criteria

Exclusion Criteria

  • Inability to provide informed consent.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiac Sarcoidosis Patients

    Patients with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis.

    Other: Exosome Analysis

Interventions

  • OtherExosome Analysis

    Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches

05

What researchers measure

Primary outcomes

  1. Number of successful biomarker validations

    Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET

    Time frame: Baseline

06

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07604220
Lead sponsor
Mayo Clinic
Responsible party
Andrew N Rosenbaum (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 22, 2026
Start date
Jul 13, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Anna Pick
Contact
pick.anna@mayo.edu
507-255-0630
Andrew Rosenbaum, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion